Comparative impact of Roux-en-Y gastric bypass, sleeve gastrectomy or diet alone on beta-cell function in insulin-treated type 2 diabetes patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
11
10
2023
accepted:
05
04
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
epublish
Résumé
Although bariatric surgery is an effective treatment for type 2 diabetes by inducing weight loss and augmenting gut hormone secretion, the immediate effect on beta-cell function itself remains to be elucidated in type 2 diabetes. Therefore, a prospective, randomized trial was performed in 30 patients with insulin-treated type 2 diabetes and a body mass index ≥ 35 kg/m
Identifiants
pubmed: 38589596
doi: 10.1038/s41598-024-59048-w
pii: 10.1038/s41598-024-59048-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8211Informations de copyright
© 2024. The Author(s).
Références
Bradley, D., Magkos, F. & Klein, S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 143, 897–912. https://doi.org/10.1053/j.gastro.2012.07.114 (2012).
doi: 10.1053/j.gastro.2012.07.114
pubmed: 22885332
Grams, J. & Garvey, W. T. Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: Mechanisms of action. Curr. Obes. Rep. 4, 287–302. https://doi.org/10.1007/s13679-015-0155-x (2015).
doi: 10.1007/s13679-015-0155-x
pubmed: 26627223
Lim, E. L. et al. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54, 2506–2514. https://doi.org/10.1007/s00125-011-2204-7 (2011).
doi: 10.1007/s00125-011-2204-7
pubmed: 21656330
pmcid: 3168743
Steven, S. et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: Pathophysiological changes in responders and nonresponders. Diabetes Care 39, 808–815. https://doi.org/10.2337/dc15-1942 (2016).
doi: 10.2337/dc15-1942
pubmed: 27002059
Taylor, R. et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery. Cell Metab 28, 547–556. https://doi.org/10.1016/j.cmet.2018.07.003 (2018).
doi: 10.1016/j.cmet.2018.07.003
pubmed: 30078554
Lean, M. E. J. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 7, 344–355. https://doi.org/10.1016/S2213-8587(19)30068-3 (2019).
doi: 10.1016/S2213-8587(19)30068-3
pubmed: 30852132
Yoshino, M. et al. Effects of diet versus gastric bypass on metabolic function in diabetes. N. Engl. J. Med. 383, 721–732. https://doi.org/10.1056/NEJMoa2003697 (2020).
doi: 10.1056/NEJMoa2003697
pubmed: 32813948
pmcid: 7456610
Dutia, R. et al. Limited recovery of beta-cell function after gastric bypass despite clinical diabetes remission. Diabetes 63, 1214–1223. https://doi.org/10.2337/db13-1176 (2014).
doi: 10.2337/db13-1176
pubmed: 24296713
pmcid: 3964502
Van der Schueren, B. J. et al. Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery. Diabetes Care 35, 42–46. https://doi.org/10.2337/dc11-1472 (2012).
doi: 10.2337/dc11-1472
pubmed: 22124715
Laferrere, B. et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 2479–2485. https://doi.org/10.1210/jc.2007-2851 (2008).
doi: 10.1210/jc.2007-2851
pubmed: 18430778
pmcid: 2453054
Casella, G. et al. Changes in insulin sensitivity and secretion after sleeve gastrectomy. Br. J. Surg. 103, 242–248. https://doi.org/10.1002/bjs.10039 (2016).
doi: 10.1002/bjs.10039
pubmed: 26550995
Guida, C. et al. PYY plays a key role in the resolution of diabetes following bariatric surgery in humans. EBioMedicine 40, 67–76. https://doi.org/10.1016/j.ebiom.2018.12.040 (2019).
doi: 10.1016/j.ebiom.2018.12.040
pubmed: 30639417
pmcid: 6413583
Rubino, F. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care 39, 861–877. https://doi.org/10.2337/dc16-0236 (2016).
doi: 10.2337/dc16-0236
pubmed: 27222544
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786. https://doi.org/10.2337/dci22-0034 (2022).
doi: 10.2337/dci22-0034
pubmed: 36148880
pmcid: 10008140
Defronzo, R. A. et al. Type 2 diabetes mellitus. Nat. Rev. Dis. Prim. 1, 15019. https://doi.org/10.1038/nrdp.2015.19 (2015).
doi: 10.1038/nrdp.2015.19
pubmed: 27189025
Purnell, J. Q. et al. Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. Diabetologia 61, 1142–1154. https://doi.org/10.1007/s00125-018-4553-y (2018).
doi: 10.1007/s00125-018-4553-y
pubmed: 29428999
pmcid: 6634312
Kashyap, S. R. et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int. J. Obes. (Lond.) 34, 462–471. https://doi.org/10.1038/ijo.2009.254 (2010).
doi: 10.1038/ijo.2009.254
pubmed: 20029383
Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am. J. Clin. Nutr. 55, 615S-619S. https://doi.org/10.1093/ajcn/55.2.615s (1992).
doi: 10.1093/ajcn/55.2.615s
DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214-223. https://doi.org/10.1152/ajpendo.1979.237.3.E214 (1979).
doi: 10.1152/ajpendo.1979.237.3.E214
pubmed: 382871
Gillard, P. et al. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. Transplantation 87, 402–407. https://doi.org/10.1097/TP.0b013e3181928a1c (2009).
doi: 10.1097/TP.0b013e3181928a1c
pubmed: 19202446
Hovorka, R., Soons, P. A. & Young, M. A. ISEC: A program to calculate insulin secretion. Comput. Methods Progr. Biomed. 50, 253–264. https://doi.org/10.1016/0169-2607(96)01755-5 (1996).
doi: 10.1016/0169-2607(96)01755-5
Kjems, L. L., Christiansen, E., Volund, A., Bergman, R. N. & Madsbad, S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49, 580–588. https://doi.org/10.2337/diabetes.49.4.580 (2000).
doi: 10.2337/diabetes.49.4.580
pubmed: 10871195
Keymeulen, B. et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc. Natl. Acad. Sci. U. S. A. 103, 17444–17449. https://doi.org/10.1073/pnas.0608141103 (2006).
doi: 10.1073/pnas.0608141103
pubmed: 17090674
pmcid: 1859948
Taylor, R., Al-Mrabeh, A. & Sattar, N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 7, 726–736. https://doi.org/10.1016/S2213-8587(19)30076-2 (2019).
doi: 10.1016/S2213-8587(19)30076-2
pubmed: 31097391
Dunn, J. P. et al. Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy. Diabetes Care 35, 137–142. https://doi.org/10.2337/dc11-1383 (2012).
doi: 10.2337/dc11-1383
pubmed: 22040841
Elahi, D. et al. Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis. 10, 1028–1039. https://doi.org/10.1016/j.soard.2014.07.011 (2014).
doi: 10.1016/j.soard.2014.07.011
pubmed: 25443077
pmcid: 10131082
Hofso, D. et al. Beta cell function after weight loss: A clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur. J. Endocrinol. 164, 231–238. https://doi.org/10.1530/EJE-10-0804 (2011).
doi: 10.1530/EJE-10-0804
pubmed: 21078684
pmcid: 3022337
Buser, A. et al. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on beta-cell function at 1 year after surgery: A systematic review. J. Clin. Endocrinol. Metab. 107, 3182–3197. https://doi.org/10.1210/clinem/dgac446 (2022).
doi: 10.1210/clinem/dgac446
pubmed: 35895383
pmcid: 9681618
Camastra, S. et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 54, 2093–2102. https://doi.org/10.1007/s00125-011-2193-6 (2011).
doi: 10.1007/s00125-011-2193-6
pubmed: 21614570
Georgia, A. et al. Roux-en-Y gastric bypass is associated with hyperinsulinemia but not increased maximal beta-cell function. J. Endocr. Soc. 3, 632–642. https://doi.org/10.1210/js.2018-00213 (2019).
doi: 10.1210/js.2018-00213
pubmed: 30834358
pmcid: 6391719
Dirksen, C. et al. No islet cell hyperfunction, but altered gut-islet regulation and postprandial hypoglycemia in glucose-tolerant patients 3 years after gastric bypass surgery. Obes. Surg. 26, 2263–2267. https://doi.org/10.1007/s11695-016-2197-x (2016).
doi: 10.1007/s11695-016-2197-x
pubmed: 27138601
Mingrone, G. et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366, 1577–1585. https://doi.org/10.1056/NEJMoa1200111 (2012).
doi: 10.1056/NEJMoa1200111
pubmed: 22449317
Castellana, M. et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for remission of type 2 diabetes. J. Clin. Endocrinol. Metab. 106, 922–933. https://doi.org/10.1210/clinem/dgaa737 (2021).
doi: 10.1210/clinem/dgaa737
pubmed: 33051679
Steenackers, N. et al. Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass. Lancet Gastroenterol. Hepatol. 6, 225–237. https://doi.org/10.1016/S2468-1253(20)30302-2 (2021).
doi: 10.1016/S2468-1253(20)30302-2
pubmed: 33581761
Holst, J. J., Gribble, F., Horowitz, M. & Rayner, C. K. Roles of the gut in glucose homeostasis. Diabetes Care 39, 884–892. https://doi.org/10.2337/dc16-0351 (2016).
doi: 10.2337/dc16-0351
pubmed: 27222546
Jimenez, A. et al. Remission of type 2 diabetes after Roux-en-Y gastric bypass or sleeve gastrectomy is associated with a distinct glycemic profile. Ann. Surg. 261, 316–322. https://doi.org/10.1097/SLA.0000000000000586 (2015).
doi: 10.1097/SLA.0000000000000586
pubmed: 25569030
Robertson, R. P. Estimation of beta-cell mass by metabolic tests: Necessary, but how sufficient?. Diabetes 56, 2420–2424. https://doi.org/10.2337/db07-0742 (2007).
doi: 10.2337/db07-0742
pubmed: 17606873
Sista, F. et al. The effect of sleeve gastrectomy on GLP-1 secretion and gastric emptying: A prospective study. Surg. Obes. Relat. Dis. 13, 7–14. https://doi.org/10.1016/j.soard.2016.08.004 (2017).
doi: 10.1016/j.soard.2016.08.004
pubmed: 27692912
Madsbad, S. & Holst, J. J. GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes 63, 3172–3174. https://doi.org/10.2337/db14-0935 (2014).
doi: 10.2337/db14-0935
pubmed: 25249642
Borgeraas, H., Hofso, D., Hertel, J. K. & Hjelmesaeth, J. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Obes. Rev. 21, e13011. https://doi.org/10.1111/obr.13011 (2020).
doi: 10.1111/obr.13011
pubmed: 32162437
pmcid: 7317556
Chang, S. H. et al. The effectiveness and risks of bariatric surgery: An updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 149, 275–287. https://doi.org/10.1001/jamasurg.2013.3654 (2014).
doi: 10.1001/jamasurg.2013.3654
pubmed: 24352617
pmcid: 3962512